COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?

Silveira, Dâmaris; Prieto-Garcia, Jose Maria; Boylan, Fabio; Estrada, Omar; Fonseca-Bazzo, Yris Maria; Jamal, Claudia Masrouah; Batista, Pérola de Oliveira Magalhães Dias; Pereira, Edson Oliveira; Tomczyk, Michal; Heinrich, Michael

Affichage complet

Élément Dublin Core	Valeur	Langue
dc.contributor.author	Silveira, Dâmaris	-
dc.contributor.author	Prieto-Garcia, Jose Maria	-
dc.contributor.author	Boylan, Fabio	-
dc.contributor.author	Estrada, Omar	-
dc.contributor.author	Fonseca-Bazzo, Yris Maria	-
dc.contributor.author	Jamal, Claudia Masrouah	-
dc.contributor.author	Batista, Pérola de Oliveira Magalhães Dias	-
dc.contributor.author	Pereira, Edson Oliveira	-
dc.contributor.author	Tomczyk, Michal	-
dc.contributor.author	Heinrich, Michael	-
dc.date.accessioned	2020-12-01T18:43:15Z	-
dc.date.available	2020-12-01T18:43:15Z	-
dc.date.issued	2020-09-23	-
dc.identifier.citation	SILVEIRA, Dâmaris et al. COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?. Frontiers in Pharmacology, v. 11, art. 581840, 23 set. 2020. DOI: https://doi.org/10.3389/fphar.2020.581840. Disponível em: https://www.frontiersin.org/articles/10.3389/fphar.2020.581840/full. Acesso em: 01 dez. 2020.	pt_BR
dc.identifier.uri	https://repositorio.unb.br/handle/10482/39687	-
dc.language.iso	Inglês	pt_BR
dc.publisher	Frontiers	pt_BR
dc.rights	Acesso Aberto	pt_BR
dc.title	COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?	pt_BR
dc.type	Artigo	pt_BR
dc.subject.keyword	Fitoterapia	pt_BR
dc.subject.keyword	Covid-19	pt_BR
dc.subject.keyword	Avaliação benefício/risco	pt_BR
dc.subject.keyword	Doenças respiratórias	pt_BR
dc.rights.license	Copyright © 2020 Silveira, Prieto-Garcia, Boylan, Estrada, Fonseca-Bazzo, Jamal, Magalhães, Pereira, Tomczyk and Heinrich. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.	pt_BR
dc.identifier.doi	https://doi.org/10.3389/fphar.2020.581840	pt_BR
dc.description.abstract1	Background: Current recommendations for the self-management of SARS-Cov-2 disease (COVID-19) include self-isolation, rest, hydration, and the use of NSAID in case of high fever only. It is expected that many patients will add other symptomatic/adjuvant treatments, such as herbal medicines. Aims: To provide a benefits/risks assessment of selected herbal medicines traditionally indicated for “respiratory diseases” within the current frame of the COVID-19 pandemic as an adjuvant treatment. Method: The plant selection was primarily based on species listed by the WHO and EMA, but some other herbal remedies were considered due to their widespread use in respiratory conditions. Preclinical and clinical data on their efficacy and safety were collected from authoritative sources. The target population were adults with early and mild flu symptoms without underlying conditions. These were evaluated according to a modified PrOACT-URL method with paracetamol, ibuprofen, and codeine as reference drugs. The benefits/risks balance of the treatments was classified as positive, promising, negative, and unknown. Results: A total of 39 herbal medicines were identified as very likely to appeal to the COVID-19 patient. According to our method, the benefits/risks assessment of the herbal medicines was found to be positive in 5 cases (Althaea officinalis, Commiphora molmol, Glycyrrhiza glabra, Hedera helix, and Sambucus nigra), promising in 12 cases (Allium sativum, Andrographis paniculata, Echinacea angustifolia, Echinacea purpurea, Eucalyptus globulus essential oil, Justicia pectoralis, Magnolia officinalis, Mikania glomerata, Pelargonium sidoides, Pimpinella anisum, Salix sp, Zingiber officinale), and unknown for the rest. On the same grounds, only ibuprofen resulted promising, but we could not find compelling evidence to endorse the use of paracetamol and/or codeine. Conclusions: Our work suggests that several herbal medicines have safety margins superior to those of reference drugs and enough levels of evidence to start a clinical discussion about their potential use as adjuvants in the treatment of early/mild common flu in otherwise healthy adults within the context of COVID-19. While these herbal medicines will not cure or prevent the flu, they may both improve general patient well-being and offer them an opportunity to personalize the therapeutic approaches.	pt_BR
Collection(s) :	Artigos publicados em periódicos e afins UnB - Covid-19